Has Ghenet Ghebretatios received payments from drug or device companies?

Yes. Drug and device makers reported $90,794 in general payments to Ghenet Ghebretatios across 1,050 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ghenet Ghebretatios did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ghenet Ghebretatios come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ghenet Ghebretatios

Family · Baton Rouge, LANPI 1356598031

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AstraZeneca at 56.5% of the total. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$90,794in general payments, 2019–2025

Across 1,050 payments — averaging $86.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$51K
Daiichi Sankyo Inc.$16K
Amgen$3K
Johnson & Johnson$2K
Pfizer$2K
E.r. Squibb & Sons, L.L.C.$2K
plus $15K from 54 others

What the payments were for

Consulting fees$4,2455%
Speaking & faculty fees$50,84056%
Travel & lodging$8,1009%
Food & beverage$26,32929%
Education$8811%
Other$3990%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	194	$51,294
Daiichi Sankyo Inc.	67	$15,637
Amgen	25	$2,892
Johnson & Johnson	59	$2,029
Pfizer	55	$1,915
E.r. Squibb & Sons, L.L.C.	44	$1,562
Novartis	69	$1,531
Exelixis Inc.	13	$1,474
Merck	49	$1,214
Genentech USA, Inc.	37	$938
Bristol Myers Squibb	43	$698
Eisai Inc.	27	$614
Sanofi	29	$583
Incyte Corporation	25	$535
Bayer	16	$506
Ipsen Biopharmaceuticals, Inc	16	$435
AbbVie	19	$403
GSK	17	$392
Regeneron Healthcare Solutions, Inc.	15	$385
Gilead	13	$340
Pharmacyclics LLC, An Abbvie Company	10	$320
Beigene USA, Inc.	12	$305
Takeda Pharmaceuticals U.S.A., Inc.	11	$295
Stemline Therapeutics Inc.	9	$280
Sanofi-aventis U.S. LLC	3	$275
Lilly USA, LLC	10	$253
Karyopharm Therapeutics Inc.	9	$228
Jazz Pharmaceuticals Inc.	7	$217
Seagen Inc.	8	$212
Blueprint Medicines Corporation	9	$199
Astellas Pharma US Inc	10	$195
Geron Corporation	4	$193
G1 Therapeutics, Inc.	6	$177
EMD Serono, Inc.	6	$161
Rigel Pharmaceuticals, Inc.	4	$159
Pharmaessentia USA Corporation	7	$152
AVEO Pharmaceuticals, Inc.	6	$122
Adaptive Biotechnologies Corporation	5	$108
Agios Pharmaceuticals, Inc.	2	$108
Novocure Inc.	1	$101
Springworks Therapeutics, Inc.	6	$101
Taiho Oncology, Inc.	5	$89
Beone Medicines USA, Inc.	5	$87
Array Biopharma Inc	7	$86
Servier Pharmaceuticals LLC	5	$86
Sobi, Inc	4	$82
Morphosys, US Inc.	5	$82
Dova Pharmaceuticals	3	$51
Boehringer Ingelheim	3	$50
Veracyte, Inc.	2	$47
Deciphera Pharmaceuticals Inc.	3	$43
Mirati Therapeutics, Inc.	3	$41
Puma Biotechnology, Inc.	2	$38
Spectrum Pharmaceuticals Inc.	2	$37
ADC Therapeutics America, Inc.	2	$37
Pharmacosmos Therapeutics Inc.	2	$37
Apellis Pharmaceuticals, Inc.	2	$37
CTI Biopharma Corp.	2	$35
Cumberland Pharmaceuticals, Inc.	2	$32
Acceleron Pharma, Inc.	2	$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Enhertu$40,547
IMFINZI$13,838
TAGRISSO$4,719
Kyprolis$2,522
Cabometyx$1,188
XTANDI$1,080
DARZALEX$259
TECVAYLI$259
OPDIVO$245
LIBTAYO$242
Erleada$230
Reblozyl$230
LENVIMA$223
Orserdu$131
JAKAFI$125
BLENREP$125
BRUKINSA$123
Tavalisse$123
Pomalyst$122
FRUZAQLA$122

How this compares

$90,794 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	79	$2,599
Oxycodone Hcl	44	$1,585
Fentanyl	14	$1,546
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	22	$969
Acyclovir	15	$570
Morphine Sulfate ErMorphine Sulfate	19	$494
Dexamethasone	21	$471
Promethazine Hcl	39	$461
Ondansetron Hcl	48	$407
Levofloxacin	14	$354
Ondansetron OdtOndansetron	26	$352
Levothyroxine Sodium	43	$273
Gabapentin	12	$184
Temazepam	21	$181
Prednisone	34	$167

Paid to pharmacies, not to this prescriber.

Other family in Baton Rouge

Elidia DewittBaton Rouge$108K
Heather SullivanBaton Rouge$32K
Randee KidderBaton Rouge$30K
Dionne BellBaton Rouge$24K
Jennifer LittleBaton Rouge$21K
Tracy ParkerBaton Rouge$19K
Kristen VillarBaton Rouge$18K
Sharon JacksonBaton Rouge$15K
Gloria MarchandBaton Rouge$14K
Stephanie ThomasBaton Rouge$14K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →